Purpose—To critically review and evaluate the science behind individual eligibility criteria
(indication/inclusion and contraindications/exclusion criteria) for intravenous recombinant …

Objective: With the emergency department (ED) being a high-risk site for diagnostic errors,
we sought to estimate ED diagnostic accuracy for identifying acute cerebrovascular events …

Background and Purpose—The authors present an overview of the current evidence and
management recommendations for evaluation and treatment of adults with acute ischemic …

Most of the contraindications to the administration of intravenous (IV) recombinant tissue
plasminogen activator (rtPA) originated as exclusion criteria in major stroke trials. These …

Background and Purpose—The acute management of stroke patients requires a fast and
efficient screening imaging modality. We compared workflow and functional outcome in …

Importance Central retinal artery occlusion (CRAO) is an ophthalmologic emergency that
can result in blindness. At present, no proven therapy for CRAO exists. Treatment with …

Intravenous recombinant tissue plasminogen activator (r-tPA) was approved for use in acute
ischemic stroke in the United States in 1996. Approximately 2% to 5% of patients with acute …

Background and Purpose—Intravenous thrombolysis for acute ischemic stroke is beneficial
within 4.5 hours of symptom onset, but the effect rapidly decreases over time, necessitating …

Introduction Thrombolysis for acute ischemic stroke (AIS) with alteplase is the currently
approved therapy for patients who present within 4.5 h of symptom onset and meet criteria …

Background and Purpose—Shortening door-to-needle time may lead to inadvertent
intravenous thrombolysis (IVT) administration in stroke mimics (SMs). We sought to …